BioCentury
ARTICLE | Translation in Brief

In the twenties

CD27 agonists help myeloid cells chow down on cancer

January 12, 2018 1:21 AM UTC

A Cancer Cell study from University of Southampton and Celldex Therapeutics Inc. (NASDAQ:CLDX) researchers suggests combining CD27 agonists with tumor-targeting mAbs could help myeloid cells attack a broad array of cancers. The partners are testing the strategy in the clinic with an anti-CD20 mAb.

Author Sean Lim told BioCentury that while CD27 is primarily known for its co-stimulatory activity on T cells, the target’s therapeutic benefits in this study were mostly due to interactions between mAbs and myeloid cells. “The whole field is focusing on the direct T cell effects of immunostimulatory antibodies, but here, we’ve uncovered a way in which T cell stimulation can benefit direct tumor-targeting antibodies.”...